Sunrise Technologies shares slump after FDA panel rejection
This article was originally published in Clinica
Executive Summary
The president and CEO of Sunrise Technologies has attempted to correct "inaccurate information" about the company following the FDA panel rejection of its laser hyperopia treatment in July (see Clinica No 868, p 15). The rejection prompted investors in the company to sell massively and critics to question its future survival prospects.